Physiowave
Melbourne, Australia· Est.
Scale‑based PWV device for fast, clinical cardiovascular risk assessment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Scale‑based PWV device for fast, clinical cardiovascular risk assessment.
Cardiovascular
Technology Platform
Scale‑based pulse wave velocity measurement using patented arterial pulse sensing, ballistocardiography, and data‑fusion algorithms to deliver PWV, pulse rate, weight, and BMI in under a minute.
Opportunities
Expansion into primary‑care networks, telehealth platforms, and home‑monitoring markets could drive rapid revenue growth as PWV becomes a standard vital sign.
Risk Factors
Regulatory reimbursement hurdles, clinician adoption inertia, and competition from established tonometry and ultrasound devices could limit market penetration.
Competitive Landscape
Key competitors include SphygmoCor, Omron, and other tonometry‑based PWV systems; PhysioWave differentiates through its scale‑form factor, workflow‑neutral design, and FDA clearance.